<DOC>
	<DOCNO>NCT01988909</DOCNO>
	<brief_summary>The objective study evaluate safety efficacy open label treatment WR 279,396 ( topical paromomycin &amp; gentamicin ) patient non-complicated , non-severe cutaneous leishmaniasis ( CL ) .</brief_summary>
	<brief_title>WR 279,396 Treatment Cutaneous Leishmaniasis</brief_title>
	<detailed_description>Patients suspect CL screen 14 day period eligibility include parasitology confirmation ulcerative CL . Recruitment primarily patient expose leishmaniasis . A target enrollment 30 patient receive WR 279,396 ( 15 % paromomycin + 0.5 % gentamicin topical cream ) daily 20 day . The index lesion ulcerate lesion assess clinical response measurement length width area ulceration . A lesion consider completely cured 100 % re-epithelialization observe . Non-ulcerated lesion also measure monitor total area exposure lesion study drug evaluate cure .</detailed_description>
	<mesh_term>Leishmaniasis</mesh_term>
	<mesh_term>Leishmaniasis , Cutaneous</mesh_term>
	<mesh_term>Gentamicins</mesh_term>
	<mesh_term>Paromomycin</mesh_term>
	<criteria>To eligible study , patient must : 1 . Be male female age 2 80 year age , inclusive . 2 . Have noncomplicated , nonsevere CL . 3 . Be able give write informed consent legal representative . 4 . Have diagnosis CL least one lesion least one follow method : 1 ) positive culture promastigotes ; 2 ) microscopic identification amastigotes stain lesion tissue and/or 3 ) positive polymerase chain reaction ( PCR ) . Patients prior diagnosis CL within 30 day start treatment eligible without confirmatory test screening . 5 . Have least one ulcerative lesion â‰¥ 1 cm &lt; 5 cm , meet criteria index lesion . 6 . Be willing forego form treatment CL include investigational treatment study . 7 . In opinion investigator , capable understanding ( legal representative ) comply protocol . 8 . Expect located area clinical site least duration screening , 20day treatment period , followup visit Days 28 +/ 2 day , 42 +/ 7 day 100 +/ 14 day . 9 . If female childbearing potential , negative serum urine pregnancy test screen agree use acceptable method birth control treatment phase 1 month treatment complete . Also , eligible study , patient must : 1 . Have prior diagnosis leishmaniasis lesion heal . 2 . Have single lesion whose characteristic include follow : verrucous nodular lesion ( nonulcerative ) , lesion &lt; 1 cm great diameter , lesion location opinion Investigator difficult maintain application study drug topically . 3 . Have lesion due leishmania involve mucosa palate . 4 . Have sign symptom disseminate disease . 5 . Be female breastfeeding . 6 . Have active malignancy history solid , metastatic hematologic malignancy exception basal squamous cell carcinoma skin remove . 7 . Have significant organ abnormality , chronic disease diabetes , severe hearing loss , evidence renal hepatic dysfunction , myasthenia gravis , parkinsonism , impairment eighth cranial nerve clinically significant level creatinine , AST , ALT judgment investigator . 8 . Have receive treatment leishmaniasis ( except mercurochrome local antiseptic ) include medication pentavalent antimony include sodium stibogluconate ( Pentostam ) , meglumine antimoniate ( Glucantime ) ; amphotericin B ( include liposomal amphotericin B amphotericin B deoxycholate ) ; WR 279,396 ; medication contain paromomycin ( administer parenterally topically ) within 56 day start study treatment , methylbenzethonium chloride ( MBCL ) ; local systemic antibiotic follow family ( penicillin , betalactamics , cyclines , synergistin , macrolides , lincosamides , fusidic acid , mupirocin ) within 8 day start study treatment . 9 . Have history know suspected hypersensitivity idiosyncratic reaction aminoglycosides . 10 . Have topical disease/condition would interfere objective study .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Cutaneous leishmaniasis</keyword>
	<keyword>Paromomycin + Gentamicin Topical Cream</keyword>
	<keyword>Safety</keyword>
	<keyword>Efficacy</keyword>
</DOC>